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NRP1 (neuropilin-1) is a co-receptor for members of the
VEGF (vascular endothelial growth factor) family in endothelial
cells, but is increasingly implicated in signalling induced by
other growth factors. NRP1 is expressed in VSMCs (vascular
smooth muscle cells), but its function and the mechanisms
involved are poorly understood. The present study aimed to
determine the role of NRP1 in the migratory response of
HCASMCs (human coronary artery smooth muscle cells) to
PDGF (platelet-derived growth factor), and to identify the
signalling mechanisms involved. NRP1 is highly expressed in
HAoSMCs (human aortic smooth muscle cells) and HCASMCs,
and modiﬁed in VSMCs by CS (chondroitin sulfate)-rich O-
linked glycosylation at Ser
612. HCASMC migration induced
by PDGF-BB and PDGF-AA was inhibited by NRP1 siRNA
(small interfering RNA), and by adenoviral overexpression of an
NRP1 mutant lacking the intracellular domain (Ad.NRP1 C).
NRP1 co-immunoprecipitated with PDGFRα (PDGF receptor
α), and immunoﬂuorescent staining indicated that NRP1 and
PDGFRα co-localized in VSMCs. NRP1 siRNA also inhibited
PDGF-induced PDGFRα activation. NRP1-speciﬁc siRNA,
Ad.NRP1 C and removal of CS glycans using chondroitinase
all inhibited PDGF-BB and -AA stimulation of tyrosine
phosphorylation of the adapter protein, p130
Cas (Cas is Crk-
associated substrate), with little effect on other major signalling
pathways,andp130
Cas knockdowninhibitedHCASMCmigration.
Chemotaxis and p130
Cas phosphorylation induced by PDGF
were inhibited by chondroitinase, and, additionally, adenoviral
expressionofanon-glycosylatableNRP1S612Amutantinhibited
chemotaxis, but not p130
Cas phosphorylation. These results
indicate a role for NRP1 and NRP1 glycosylation in mediating
PDGF-induced VSMC migration, possibly by acting as a co-
receptor for PDGFRα and via selective mobilization of a novel
p130
Cas tyrosine phosphorylation pathway.
Key words: chemotaxis, glycosylation, neuropilin-1 (NRP1),
p130
Cas, platelet-derived growth factor (PDGF), vascular
endothelial growth factor (VEGF).
INTRODUCTION
NRP1 (neuropilin-1) is a transmembrane co-receptor with
essential roles in neural pathﬁnding and cardiovascular
development [1–3]. NRP1 is a receptor for Sema3A (semaphorin
3A),amemberofafamilyofproteinsinvolvedinaxonalguidance
[4,5], and for VEGF (vascular endothelial growth factor)-A165
and other members of the VEGF family of angiogenic cytokines,
including the heparin-binding PlGF-2 (placental growth factor 2)
isoform,VEGF-BandVEGF-E[6,7].NRP2hasasimilardomain
structure to that of NRP1 with 44% amino acid identity, and
is also expressed in endothelial, tumour and neuronal cells, but
exhibits a distinct expression pattern in the developing nervous
system [5,8,9]. Studies of NRP1 function in endothelial cells
are generally indicative of a key role of NRP1 in VEGF-
dependent cell migration. NRP1 is thought to act as a co-
receptor for VEGF by forming complexes with the VEGF protein
tyrosine kinase receptor, VEGFR2 (VEGF receptor 2)/KDR
(kinase insert domain-containing receptor), resulting in enhanced
VEGFR2 activation, intracellular signalling, cell migration and
angiogenesis [10–13].
Various evidence indicates that NRP1 plays a role in the
functions of VSMCs (vascular smooth muscle cells). NRPs
are expressed and up-regulated by FGF-2 (ﬁbroblast growth
factor 2) and PDGF (platelet-derived growth factor)-BB in
VSMCs [14–16]. It was also reported that NRP1 can be co-
immunoprecipitated with PDGF-BB [15]. However, the role
of NRP1 in PDGF-regulated functions in VSMCs is poorly
characterized,andthemechanismsthroughwhichNRP1regulates
PDGF actions are not known. In the present study, we examined
the expression of NRP1 in VSMCs and its role in VSMC
migration. NRP1 is highly expressed in HAoSMCs (human aortic
smooth muscle cells) and HCASMCs (human coronary artery
smooth muscle cells), both as the more usual full-length form of
130 kDa and as a high-molecular-mass species modiﬁed by O-
linked glycosylation [16]. Importantly, we show that inhibition of
NRP1 function signiﬁcantly decreases the migratory response
to PDGF-BB. Adenoviral overexpression of an NRP1 mutant
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lacking the C-terminal intracellular domain also inhibited PDGF-
BB-induced migration, suggesting an important role for NRP1-
dependent intracellular signalling in this role. Furthermore, we
show that NRP1 associates with PDGFR (PDGF receptor) α
in HCASMCs, and that NRP1 inhibition reduces PDGF-BB
signalling through p130
Cas (Cas is Crk-associated substrate),
an adaptor protein with important roles in cell migration [17],
and which we recently showed to be regulated by NRP1
overexpression in the invasion of U87MG glioma cells [18].
PDGF-induced migration was also inhibited by expression of a
non-glycosylatable NRP1S612A mutant. These ﬁndings indicate
a novel role for NRP1 and NRP1 O-linked glycosylation in the
VSMCchemotacticresponsetoPDGF-BBandsuggestthatNRP1
is critical for optimal PDGF signalling through p130
Cas which is
important for migration.
MATERIALS AND METHODS
Materials
siRNAs (small interfering RNAs) were purchased from
Ambion and an electroporation kit (Amaxa) was used for
VSMC transfection. Chondroitinase ABC and heparinase III
(heparitinase) were from Sigma, and the following antibodies
were from Santa Cruz Biotechnology: anti-NRP1 (C-19), anti-
NRP2 (C-9), anti-Flk-1 (N-19), anti-synectin/GIPC [GAIP
(Gα-interacting protein)-interacting protein C-terminus] (C-
1158), PDGFRβ (PDGF receptor β), PDGFRα (C-20),
GAPDH (glyceraldehyde-3-phosphate dehydrogenase) (V-18)
and secondary antibodies against goat, rabbit and mouse. Anti-
p130
Cas (total) antibody was from BD Biosciences; antibodies
against phospho-p130
Cas (pTyr
410), phospho- and total Akt and
phospho- and total ERK (extracellular-signal-regulated kinase)
1/2 were from Cell Signaling Technology; antibody against the
NRP1N-terminaldomainwasfromR&DSystems,andantibodies
against CS (chondroitin sulfate) and HS (heparan sulfate) were
from Sigma and Seikagu respectively.
Cell culture
HCASMCs and HCAECs (human coronary artery endothelial
cells), HAoSMCs and HUVECs (human umbilical vein
endothelial cells) (all from TCS CellWorks), were cultured in
HumanVSMCbasalmediumcontaininggrowthsupplementsplus
2.5% (v/v) FBS (fetal bovine serum), or large vessel endothelial
basalmediumcontaining10%(v/v)FBS,gentamycin(25 μg/ml)
and amphotericin B (50 μg/ml). PAE (porcine aortic endothelial)
cells were cultured in Ham’s F12 medium containing 10% (v/v)
FBS, supplemented for PAE/NRP1 cells (PAE cells expressing
NRP1) with 25 μg/ml hygromycin B. Cells used in experiments
were up to passage six for endothelial cells and passage ﬁve for
VSMCs.
Cell treatments
All treatments with growth factors (e.g. PDGF) were performed
in serum-free medium and in the absence of other growth
factors unless stated otherwise, and were also performed after
incubation of cells for 16 h (overnight) in serum-free medium.
Cells were incubated with 5 μg/ml tunicamycin for 16 h, or with
chondroitinaseandheparitinaseat1 unit/mlfor2 hat37◦C.Cells
were then lysed with RIPA buffer (30 mM Tris/HCl, pH 7.4,
150 mMNaCl,1%NonidetP40,0.5%sodiumdeoxycholateand
2 mM ETDA), and VSMCs were lysed with lysis buffer (20 mM
sodium phosphate, pH 7.4, 150 mM NaCl, 1% Triton X-100
and 5 mM EDTA), supplemented with protease and phosphatase
inhibitors. NRP1 immunoprecipitates were treated overnight
at 37◦C with 1 unit/ml chondroitinase or heparitinase in 1%
Nonidet P40, 0.15 M NaCl, 0.05 mM CaCl2 and 20 mM Tris/HCl
(pH 7.2). Immunoprecipitates were then washed three times with
lysis buffer and resuspended in 2× electrophoresis sample buffer
for protein analysis.
Immunoprecipitation
HCASMCs were extracted in lysis buffer, and lysates were
incubated with primary antibodies overnight at 4◦C, washed
three times in lysis buffer, and captured with Protein A/G
Plus–agarose beads (Santa Cruz Biotechnology) for 3 h at
4◦C. Immunoprecipitates were washed and subjected to various
treatmentsasdescribed,beforesolubilizationin2×samplebuffer
and analysis by Western blotting.
Western blotting
Cell lysates were separated by electrophoresis on 4–12% Bis-
Tris polyacrylamide gels, and electrotransferred on to PVDF
membranes. Membranes were blocked with 5% (w/v) non-
fat dried milk in PBS containing 0.1% Tween 20, incubated
with primary antibodies overnight, washed ﬁve times in PBS
containing 0.1% Tween 20, incubated for 1 h with horseradish
peroxidase-labelled IgG, and proteins were detected using the
ECL Plus
TM Western blotting detection system and Hyperﬁlm
ECL (both Amersham Biosciences).
Flow cytometry
HUVECs and HCASMCs were dissociated using non-enzymatic
dissociation buffer, resuspended in blocking buffer (1%
BSA/Hepes with FcR-blocking reagent, Miltenyi Biotech), and
incubated with primary antibodies for 20 min at 4◦C. All
antibodies were conjugated to phycoerythrin, used at a 1:10
dilution, and antibodies of the same isotype (mouse IgG1)w e r e
used as controls. Cells were then washed with PBS containing
0.2% BSA, pelleted by centrifugation at 1000 g for 5 min
and resuspended in PBS, 1% BSA, 20 mM Hepes and 7AAD
(7-aminoactinomycin D) (1:100 dilution; Sigma–Aldrich). Cells
were then analysed using a Becton Dickinson FACScan ﬂow
cytometer with CellQuestPro software.
Immunoﬂuorescent staining
Cells were ﬁxed for 15 min in 4% (w/v) paraformaldehyde,
permeabilizedfor10 minwith0.1%TritonX-100,thenincubated
overnight at 4 ◦C with primary antibodies in 0.1% Tween 20
and 1% BSA in PBS, and then incubated for 1 h in the dark
with Alexa Fluor® 488-conjugated donkey anti-goat IgG and/or
AlexaFluor® 555-conjugateddonkeyanti-mouseIgG(Invitrogen
Molecular Probes). Cells were then rinsed three times with PBS,
and images were acquired using a Leica TCS SP2 confocal
microscope (excitation at 488 nm and 543 nm).
Transfection with siRNAs
Transfection of HCASMCs was performed using a
Nucleofector
TM kit for mammalian smooth muscle cells
(Amaxa). A total of 10
6 cells were resuspended in 100 μlo ft h e
proprietary transfection reagent supplied with the Amaka kit with
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200 nM siRNA, and transfected according to the manufacturer’s
instructions. Cells were transferred to six-well plates and used
experimentally 72 h after transfection.
Mutagenesis and adenoviruses
Adenoviruses expressing wild-type NRP1 (Ad.NRP1WT),
NRP1 lacking the intracellular domain (Ad.NRP1 C) and
NRP1S612A (Ad.NRP1S612A) were generated using the
Gateway® system (Invitrogen). NRP1 open reading frames were
subclonedintothepENTR/D-TOPOvectorbyPCRampliﬁcation
with primers designed according to the manufacturer’s
instructions (forward, 5
 -CACCATGGAGAGGGGGCTGCC-3
 ;
reverse, 5
 -TCATGCCTCCGAATAAGTACTCTGTG-3
 )u s i n g
TOPO cloning (Invitrogen). NRP1 adenoviral expression
vectors (pAd/CMV/V5-DEST) (Invitrogen) were generated by
recombination, and adenovirus was produced by transfection into
host HEK (human embryonic kidney)-293A cells (Invitrogen).
Viral particles were puriﬁed by caesium chloride centrifugation,
thetitrewasdeterminedbyimmunoassay(QuickTiterAdenovirus
Titer Immunoassay kit, Cell Biolabs), and adenoviruses were
stored at −20◦C.
PDGFR activity assay
Intact HCASMCs were treated with growth factors as described
in the Results and Figure legends and lysed, and activities
of PDGFRα and PDGFRβ were determined in cell lysates
using speciﬁc DuoSet IC ELISAs (R&D Systems) for tyrosine-
phosphorylated PDGFRα and PDGFRβ according to the
manufacturer’s instructions. See the Supplementary Online
Data at http://www.BiochemJ.org/bj/435/bj4350609add.htm for
further details.
Migration assay
A transwell assay was used to assess cellular migration through
a porous membrane. Before migration assays, HCASMCs were
treated with siRNAs, adenoviruses or as indicated. Transwells
were coated with collagen (0.01%, Sigma) overnight at 4 ◦C.
HCASMCs were grown to 80% conﬂuence, detached with non-
enzymatic cell dissociation buffer and resuspended in serum-free
VSMC medium before transfer into the transwells (8 μm pore
size, 6.4 mm diameter, VWR) at a density of 1.5×10
5 cells/ml.
Chemoattractants were placed in the bottom of the transwell,
and cells were allowed to migrate for 4 h, after which non-
migrated cells were removed from the upper surface of the
transwell membrane using a cotton bud, and migrated cells
were stained with Reastain Quick-Diff Kit (Reagena), and
countedunderbrightﬁeldmicroscopy(×200magniﬁcation).Each
experiment was performed at least three times (n=3), with each
treatment performed in duplicate.
Surface protein biotin labelling and afﬁnity selection
HCASMC surface membrane proteins were isolated using
a surface protein isolation kit (Pierce) according to the
manufacturer’s instructions. Brieﬂy, intact adherent HCASMCs
werelabelledat4◦Cfor30 minwithacell-impermeablecleavable
biotinylation reagent that covalently links functional amines
of proteins. Biotinylation was then stopped by addition of
quenching solution, cells were washed once with ice-cold PBS,
and then lysed and sonicated. The cell lysate was incubated with
NeutrAvidin Agarose for 60 min at room temperature (23◦C),
followed by solublization of the labelled surface proteins with
Figure 1 Neuropilin expression and glycosylation in human VSMCs and
endothelial cells
(A)Whole-celllysatesofHUVECs,HCAECs,HCASMCsandHAoSMCswereimmunoblottedfor
NRP1,NRP2,VEGFR2,synectin,PDGFRα,PDGFRβ andGAPDH.NRP1bandsofapproximately
130kDa and >250kDa are indicated. (B) Cell-surface expression of NRP1 was examined in
HUVECs and HCASMCs using ﬂow cytometry as described in the Supplementary Online Data
at http://www.BiochemJ.org/bj/435/bj4350609add.htm. KDR, kinase insert domain-containing
receptor (VEGFR2); PE, phycoerythrin. (C) Conﬂuent cultures of the cells indicated were
pre-treated with (+) or without (−)5μg/ml tunicamycin for 16h. Lysates were then prepared
and immunoblotted with an antibody against NRP1 or NRP2. (D) Top and middle: HCASMCs
were treated with chondroitinase, heparitinase or both enzymes combined (each at 1 unit/ml)
for 4h, and lysates were prepared and immunoblotted with an antibody against NRP1 or
GAPDH. Bottom: NRP1 immunoprecipitates prepared from HCASMCs were incubated for 4 h
with chondroitinase or heparitinase, and then immunoblotted with anti-NRP1 antibody. WB,
Westernblot;IP,immunoprecipitate.Resultsshownin(A)–(D)arerepresentativeofatleastthree
independentexperiments.MolecularmassesareindicatedinkDa.(E)AmountsofGAG-modiﬁed
NRP1 after chondroitinase or heparitinase treatments in the Western blots shown in (D)w e r e
quantiﬁedbyscanningdensitometry,andusedtocalculatetherelativelevelsofunmodiﬁedNRP1,
HS-GAG–NRP1andCS-GAG–NRP1inHCASMCs.ResultsaremeanpercentagesoftotalNRP1
immunoreactivity (non-GAG-modiﬁed 130kDa NRP1 plus GAG-modiﬁed >250kDa NRP1).
sample buffer and heat treatment for 5 min at 95◦Cb e f o r e
SDS/PAGE (4–12% gradient gels) and Western blotting.
Statistical analysis
Results are presented as means+S.E.M. Statistical analysis
was performed by one-way ANOVA with Bonferroni post test.
Statistical signiﬁcance was validated at P<0.05.
RESULTS
Expression of neuropilins
NRP1 and the neuropilin-interacting protein, synectin, were
expressed in HCASMCs, HAoSMCs, HCAECs and HUVECs
(Figure 1A). In contrast, the major signalling VEGF receptor,
VEGFR2, was expressed at very low levels in HCASMCs and in
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Figure 2 NRP1 plays a role in PDGF-induced VSMC chemotaxis
HCASMCs were transfected with siRNA to NRP1, NRP2 or synectin (syn), or with control non-targeted scrambled siRNA (Scr), and 3days later were either transferred to transwells and allowed to
migrate for 4h in response to 30ng/ml PDGF-BB (A and B), 30ng/ml PDGF-AA (B) or serum-free medium (Control), or were used to assess expression of targeted proteins by immunoblotting of
whole-celllysates (A,bottom).Resultsaremean+S.E.M.(n=3)numbersofmigratedcellsobtainedfrommultipleindependentexperiments.*P <0.05comparedwithScr siRNAplusPDGF-BBor
PDGF-AA.Representativetranswellﬁltersshowingstainedmigratedcellsareshownabovethehistogram.Proteinexpression3daysaftersiRNAtransfectionwasquantiﬁedbyscanningdensitometry
of blots from three independent experiments (A, bottom right).
HAoSMCs in comparison with both endothelial cell types. NRP2
was expressed in HCASMCs, but was barely detectable in HAoS-
MCs (Figure 1A). In addition to the normal full-length NRP1
bandof130 kDa,ahigh-molecular-mass(>250 kDa)NRP1band
was prominent in HCASMCs and HAoSMCs, but not detectable
in endothelial cells (Figure 1A). A high-molecular-mass NRP1
species was previously reported in VSMCs and in tumour
cell lines [16,18], but anti-NRP2 antibody did not recognize a
similar band (Figure 1A). Flow cytometry veriﬁed that NRP1
was expressed in HCASMCs and HUVECs at the cell surface,
whereassurfaceVEGFR2expressionwasverylowinHCASMCs,
but high in HUVECs (Figure 1B). In contrast, PDGFRα and
PDGFRβ were expressed in HAoSMCs and HCASMCs, with
higher expression of both receptors in HAoSMCs, but were not
detected in endothelial cells (Figure 1A).
VSMC neuropilins are O- and N-glycosylated
Treatment with tunicamycin, which blocks addition of
carbohydrates to asparagine residues, caused a small reduction
in the apparent molecular mass of both the >250 kDa and
130 kDa NRP1 bands, and similarly decreased the apparent
molecular mass of NRP2, indicating that NRP1 and NRP2
are modiﬁed by N-glycosylation (Figure 1C). Removal of O-
linked GAGs (glycosaminoglycans) containing CS by treatment
of intact cells or NRP1 immunoprecipitates with chondroitinase
markedly reduced expression of the >250 kDa NRP1 band, and
concomitantlyincreasedexpressionofthe130 kDaband,whereas
heparitinase, which removes HS-GAGs, had less effect, and
chondroitinase and heparitinase together completely removed the
>250 kDa band (Figure 1D). These results indicate that
the high-molecular-mass NRP1 band in HCASMCs results
predominantly from post-translational modiﬁcation by CS-GAGs
with less addition of HS-GAGs (Figure 1E). Immunoﬂuorescent
staining of NRP1, CS and HS showed that, in HCASMCs,
both CS and HS co-localized with NRP1 in the cytoplasm,
particularly in perinuclear Golgi-like structures, and at the
cell membrane (see Supplementary Figures S1A and S1B
athttp://www.BiochemJ.org/bj/435/bj4350609add.htm),whereas
little co-localization of NRP1 and CS was observed in HUVECs
(Figure S1C).
Role of NRP1 in HCASMC migration
Since VEGF is reported to stimulate migration of VSMCs
[16,19,20], we addressed the possibility that NRP1 could mediate
cell migration induced by VEGF in HCASMCs. VEGF exhibited
speciﬁchigh-afﬁnitybindingtoHCASMCculturesasdetermined
by radiolabelled ligand binding (see Supplementary Table S1 at
http://www.BiochemJ.org/bj/435/bj4350609add.htm). However,
VEGF-A165 at concentrations of 25–200 ng/ml, caused no
signiﬁcant increase in HCASMC migration, whereas the potent
VSMC chemoattractant PDGF-BB induced a marked increase in
HCASMCmigrationat30 ng/ml(seeSupplementaryFiguresS2A
andS2Bathttp://www.BiochemJ.org/bj/435/bj4350609add.htm).
Inaddition,whereasPDGF-AAandPDGF-BBinducedastriking
increase in ERK1/2 and Akt activation in HCASMCs, VEGF-
A165 in the concentration range 25–100 ng/ml had little, if any,
signiﬁcant effect on ERK and Akt activity (see Supplementary
Figure S2C). In parallel experiments in HUVECs, VEGF-A165
c   The Authors Journal compilation c   2011 Biochemical Society © 2011 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.Neuropilin mediates PDGF-induced migration and signalling 613
induced strong ERK1/2 and Akt activation, whereas neither
PDGF-AA nor PDGF-BB had any detectable effect in HUVECs
(see Supplementary Figure S2C).
The role of NRP1 in the migratory response of HCASMCs
to PDGF-BB was examined by siRNA-mediated knockdown
of NRP1 and NRP2. Transfection of HCASMCs with siRNAs
targeted to NRP1 and NRP2 signiﬁcantly reduced NRP protein
expression in HCASMCs (Figure 2A). When siRNA-transfected
HCASMCs were used in migration assays, NRP1 knockdown
caused a signiﬁcant decrease in migration in response to
PDGF-BB (Figure 2A). NRP2 siRNA signiﬁcantly inhibited the
migratory response to PDGF-BB, although somewhat less than
did NRP1 (Figure 2A). Synectin knockdown caused a small and
statistically insigniﬁcant reduction in the PDGF-BB response
(Figure 2A). PDGF-AA-induced migration was also signiﬁcantly
reduced by NRP1 siRNA (Figure 2B).
The NRP1 cytosolic domain has been implicated in the
functions of NRP1 in endothelial cells [21]. To substantiate
further the role of NRP1 in the PDGF-BB migratory response in
HCASMCs,weexaminedtheeffectsofadenoviraloverexpression
of wild-type NRP1 and a mutant NRP1 lacking the cytosolic
domain. Infection of HCASMCs with Ad.NRP1WT resulted in a
signiﬁcant increase in protein expression above the endogenous
level (Figure 3A), but did not signiﬁcantly alter the migration of
HCASMCs towards a gradient of either PDGF-AA or PDGF-BB,
compared with control cells infected with Ad.GFP (adenovirus
expressing green ﬂuorescent protein) (Figure 3B). In contrast,
Ad.NRP1 C infection, resulting in overexpression of NRP1
lacking the intracellular domain (Figure 3A), caused a signiﬁcant
inhibition of cell migration induced either by PDGF-AA or by
PDGF-BB(Figure3B),similartotheeffectofNRP1knockdown.
It was also noted that Ad.NRP1 C overexpression also reduced
the basal level of HCASMC migration seen in the absence of
PDGF stimulation.
PDGF-BB has been reported to co-immunoprecipitate
with NRP1 [15], suggesting that PDGF-BB might bind
directly to NRP1. We investigated this possibility by determining
the speciﬁc ligand binding of
125I-PDGF-BB to PAE/NRP1
cells.Whereas
125I-PDGF-BB showedsigniﬁcantspeciﬁcbinding
to HCASMCs,
125I-PDGF-BB exhibited little speciﬁc binding to
PAE/NRP1 cells above the level observed in wild-type PAE cells
not expressing NRP1 (see Supplementary Table S1). It was also
noted that a high percentage of the total
125I-PDGF-BB binding to
PAE and PAE/NRP1 cells was non-speciﬁc.
PDGFRα and NRP1 associate in HCASMCs
As shown in Figure 1(A), HCASMCs express PDGFRα and
PDGFRβ, either of which can mediate responses to PDGF-
BB, whereas PDGFRβ does not recognize PDGF-AA with
high afﬁnity. A mechanism through which NRP1 could regulate
migratory responses of HCASMCs to PDGF is the formation
of heterocomplexes between PDGFRs and NRP1. To examine
this possibility, we co-immunoprecipitated NRP1 with PDGFRs
from HCASMC lysates. An NRP1 immunoblot of PDGFRα
immunoprecipitates detected signiﬁcant NRP1 compared with
IgG controls, indicating that PDGFRα associated with NRP1
(Figure 4A). Treatment of HCASMCs with PDGF did not
signiﬁcantly affect the level of NRP1 co-immunoprecipitation
with PDGFRα. Co-immunoﬂuorescent staining of NRP1 and
PDGFRα in HCASMCs also revealed signiﬁcant co-localization
of these molecules at the cell membrane, consistent with
the conclusion that they associate (Figure 4B). We could
not detect NRP1 in PDGFRβ immunoprecipitates (results not
shown), and co-staining of NRP1 and PDGFRβ revealed little
Figure 3 Overexpression of NRP1 lacking the cytosolic domain inhibits
VSMC chemotaxis
HCASMCs were either uninfected (Control) or infected with Ad.GFP, Ad.NRP1WT or
Ad.NRP1 C. At 3days after infection, cell lysates were prepared and immunoblotted with
antibodies speciﬁc for the NRP1 C- or N-terminus (A), or were transferred to transwells and
allowed to migrate for 4h in response to serum-free medium (control) or 30ng/ml PDGF-AA
or PDGF-BB (B). Results are mean+S.E.M. (n=3) numbers of migrated cells obtained from
multiple independent experiments. *P <0.05 compared with Ad.NRP1WT plus PDGF-AA or
PDGF-BB. Molecular masses in kDa are indicated in (A).
signiﬁcant co-localization (see Supplementary Figure S3 at
http://www.BiochemJ.org/bj/435/bj4350609add.htm).
Role of NRP1 in PDGF-BB chemotactic signalling via p130Cas
In order to understand further the mechanism through
which NRP1 regulates PDGDF-BB chemotactic signalling, we
investigated the contribution of NRP1 to PDGF-BB-stimulated
chemotactic cell signalling in HCASMCs. We ﬁrst examined
whether NRP1 is required for activation of PDGFRs in VSMCs,
by determining the effect of NRP1 knockdown on PDGF-
induced receptor activation in a quantitative ELISA speciﬁc
for phosphorylation of PDGFRα and PDGFRβ. The results
indicate that NRP1 knockdown markedly inhibited PDGF-AA
stimulationofPDGFRα activityandsigniﬁcantlyreducedPDGF-
BB induction of PDGFRα activity, although the effect of NRP1
siRNA on the response to PDGF-BB was noticeably smaller
than for PDGF-AA (Figure 5A, upper panel). In contrast, NRP1
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Figure 4 NRP1 associates with PDGFRα in HCASMCs
(A) HCASMCs were incubated in serum-free medium overnight, then treated with (+)o r
without (−) 30ng/ml PDGF-BB for 10min. Cells were then lysed and PDGFRα was
immunoprecipitated (IP). In parallel, lysates were incubated with either secondary antibody
alone (IgG), or agarose beads alone. Immunoprecipitates were then immunoblotted (WB) with
anti-NRP1 or anti-PDGFRα antibodies. Results are representative of at least three independent
experiments. Molecular masses are indicated in kDa. (B) HCASMCs were ﬁxed, permeabilized
andthenimmunostainedforNRP1(green)andPDGFRα (red).Thelowerleft-handpanelshows
a merge of immunostaining for NRP1 and PDGFRα, and an enlarged image of the region in
the green square is shown in the lower right-hand panel. Areas of co-localization at the cell
membrane are indicated by white arrowheads. The results shown are representative of at least
three independent experiments.
siRNA had no signiﬁcant effect on PDGF-BB-induced PDGFRβ
phosphorylation (Figure 5A, lower panel). It was conﬁrmed
that PDGF-AA did not stimulate PDGFRβ phosphorylation. To
determine whether effects of NRP1 knockdown were due to
decreased surface receptor expression, we performed biotinyla-
tion of cell-surface receptors and their subsequent isolation using
avidin–agarose beads. As shown in Figure 5(B), whereas NRP1
knockdown markedly reduced surface biotinylated NRP1, it had
onlyamodesteffectonsurfacePDGFRα expressionandhadlittle
detectable effect on PDGFRβ expression.
WereportedpreviouslythatoverexpressionofNRP1inU87MG
glioma cells enhanced signalling through the adapter protein
p130
Cas [18], which is strongly implicated in cell migration
and invasion [17]. PDGF-BB and PDGF-AA increased p130
Cas
Figure 5 NRP1 knockdown inhibits PDGFRα activation
(A) HCASMCs were transfected with control scrambled siRNA (Scr) or with NRP1 siRNA, and
3 days later, cells were incubated overnight in serum-free medium and then treated for 10 min
with serum-free medium (control), 30ng/ml PDGF-AA or 30ng/ml PDGF-BB. Cells were then
lysed, and the activity of either PDGFRα (upper) or PDGFRβ (lower) was measured using
a speciﬁc ELISA. Results are means+S.E.M. obtained from three independent experiments
each performed in triplicate. *P <0.05 compared with Scr siRNA plus PDGF-BB or PDGF-AA.
(B) HCASMCs were transfected with siRNA as indicated, and 3 days later, intact cells were
surface labelled with biotin. Biotinylated surface membrane proteins were isolated and then
immunoblotted as indicated. Molecular masses are indicated in kDa.
tyrosine phosphorylation in HCASMCs, consistent with this
pathwayplayingaroleintheirchemotacticresponses(Figure6A).
VEGF had little effect on p130
Cas tyrosine phosphorylation
in HCASMCs in a direct comparison with PDGF-BB (see
Supplementary Figure S2). Depletion of NRP1 by siRNA-
mediated knockdown signiﬁcantly reduced p130
Cas tyrosine
phosphorylation stimulated by PDGF-BB or -AA, but had
little effect on PDGF-induced activation of ERK1/2 or Akt
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Figure 6 PDGF-stimulated p130Cas phosphorylation is mediated via NRP1
(A and B) HCASMCs were transfected with control scrambled siRNA (Scr) or with NRP1 siRNA, and 3 days later, cells were incubated overnight in serum-free medium (SF) and then treated for
10 min with 30ng/ml PDGF-BB or 30ng/ml PDGF-AA. Cells were then lysed and immunoblotted with the antibodies indicated. Results are representative of at least three independent experiments.
p130Cas tyrosine phosphorylation in three independent experiments similar to those in (A) were quantiﬁed by scanning densitometry (B). *P <0.05 compared with Scr siRNA plus PDGFs.
(C and D) HCASMCs were infected with Ad.GFP, Ad.NRP1WT or Ad.NRP1 C. At 3days after infection, cells were incubated overnight in serum-free medium and then treated for 10 min with either
serum-freemediumorwith30ng/mlPDGF-BBfor10min.CellswerethenlysedandimmunoblottedwithantibodiesspeciﬁcfortheNRP1N-terminus,totalandphosphorylatedp130Cas andGAPDH
asindicated.Resultsfromthreeindependentexperimentssimilartothosein(C)wereusedforquantiﬁcationofp130Cas tyrosinephosphorylationusingscanningdensitometry(D).Molecularmasses
in kDa are indicated in (A)a n d( C). RU, relative units.
(Figures 6A and 6B and see Supplementary Figure S4 at
http://www.BiochemJ.org/bj/435/bj4350609add.htm). We noted
that the effect of PDGF-AA on p130
Cas tyrosine phosphorylation
was weaker than that of PDGF-BB (Figure 6B). The role
of the NRP1 cytosolic domain in p130
Cas signalling was
examined by overexpressing the NRP1 Cm u t a n t .A ss h o w ni n
Figure 6(C), Ad.NRP1 C inhibited PDGF-BB-induced p130
Cas
tyrosine phosphorylation. Quantiﬁcation of data from several
independent experiments showed that Ad.NRP1 Cm a r k e d l y
and signiﬁcantly reduced the stimulation of p130
Cas tyrosine
phosphorylation by PDGF-BB (Figure 6D). In contrast, it was
notedthatAd.NRP1WToverexpressionwasassociatedwithsome
enhancement of p130
Cas tyrosine phosphorylation, although the
effect of Ad.NRP1WT was not statistically signiﬁcant. Whereas
p130
Cas isimplicatedinthemechanismsunderlyingcellmigration
andassociatedcellularprocessessuchascytoskeletalorganization
[17], the role of this adapter protein in VSMC migration has
been little investigated. As shown in Figure 7, p130
Cas siRNA
signiﬁcantly reduced the migratory response of HCASMCs
to PDGF-BB by an amount similar to the effect of NRP1
knockdown, and also reduced the increase in migration induced
by PDGF-AA, although the latter effect was not statistically
signiﬁcant.
We also examined the possibility that NRP1 CS modiﬁcation
played a role in PDGF chemotactic signalling via p130
Cas,
by enzymatically removing CS-rich glycan moieties using
chondroitinase. Chondroitinase treatment of intact cells
signiﬁcantly reduced the stimulation of VSMC chemotaxis by
PDGF-BB (Figure 8A), and also reduced the induction of
p130
Cas tyrosine phosphorylation by PDGF-BB and PDGF-AA
(Figure 8B). Removal of HS-rich glycans using heparitinase had
no signiﬁcant effect on PDGF-BB-induced migration (results not
shown),andalsohadnodetectableeffectonstimulationofp130
Cas
tyrosine phosphorylation (Figure 8B). To examine the role of
NRP1 CS-GAG modiﬁcation speciﬁcally, we used an adenoviral
vector expressing a non-glycosylatable NRP1S612A mutant.
Ad.NRP1S612Aresultedinoverexpressionofthe130 kDaNRP1
species to a level similar to that resulting from Ad.NRP1WT
expression, but with no concomitant increase in the 250 kDa
NRP1 CS-GAG species (Figure 8C). However, overexpression
of Ad.NRP1S612A signiﬁcantly inhibited migration induced by
PDGF-AA and PDGF-BB compared with NRP1WT (Figure 8C).
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Figure 7 PDGF-BB-induced VSMC chemotaxis is mediated via p130Cas
HCASMCs were transfected with control scrambled siRNA (Scr) or with p130Cas siRNA, and
3 days later, cells were transferred to transwells and allowed to migrate for 4h in response to
30ng/mlPDGF-BB,30ng/mlPDGF-AAorserum-freemedium(Control),orwereusedtoassess
expression of targeted proteins by immunoblotting of whole-cell lysates (right). Migration of
transfected cells was measured as described in the Materials and methods section. Results are
mean+S.E.M. numbers of migrated cells obtained from three independent experiments, each
performed in triplicate. *P <0.05 compared with Scr siRNA plus PDGF-BB. Immunoblots are
representative of three independent experiments.
We also examined the effect of the NRP1S612A mutant on PDGF
stimulation of p130
Cas tyrosine phosphorylation, but could detect
no consistent or signiﬁcant inhibition (results not shown).
DISCUSSION
NRP expression has been reported in VSMCs and to play a role in
VSMC migration [15], but the mechanism through which NRP1
regulatesVSMCmigrationispoorlyunderstood.Thekeyﬁndings
of the present study are that NRP1 plays a signiﬁcant role in the
stimulation of human VSMC migration by the potent VSMC
chemoattractants PDGF-AA and PDGF-BB, and in chemotactic
PDGF signalling in VSMCs via p130
Cas.
The conclusion that NRP1 is important for PDGF-BB-induced
HCASMC migration is supported by the effects of NRP1
siRNA and mutant NRP1 overexpression: NRP1 knockdown
and overexpression of NRP1 lacking the cytoplasmic domain
(NRP1 C) both signiﬁcantly inhibited HCASMC migration
induced either by PDGF-AA or by PDGF-BB. Since the
NRP1 cytoplasmic domain is known to mediate protein–protein
interactions, the fact that an NRP1 construct lacking this domain
inhibited the migratory response to PDGF-BB suggests that
NRP1 is required for optimal signalling important for migration
downstream of PDGFRs. We noted that Ad.NRP1 C expression
hadamoremarkedinhibitoryeffectonPDGF-inducedHCASMC
migration than did NRP1 siRNA, and also reduced the basal
unstimulated level of migration, whereas NRP1 siRNA did
not. These results are consistent with the conclusion that the
NRP1 C mutant exerts a dominant-negative effect, possibly via
preventionofinteractionsbetweentheNRP1cytoplasmicdomain
and intracellular binding partners important for transducing
chemotactic signals and/or sequestration in inactive complexes of
PDGF,PDGFRandpossiblyothercellularcomponentsimportant
for chemotactic signalling. The only known NRP1 cytosolic
domain-binding molecule is synectin, and our ﬁndings show that
synectin knockdown reduced PDGF-BB-induced cell migration,
although this effect did not reach statistical signiﬁcance. Other
proteins may interact with the NRP1 cytoplasmic domain and
contribute to PDGF-BB chemotactic signalling.
Although PDGF-BB has been reported to coimmuno-
precipitate with NRP1 [15], we did not ﬁnd convincing
evidence that PDGF-BB binds directly to NRP1 either in
co-immunoprecipitation, or in studies of radiolabelled PDGF-
BB binding to PAE/NRP1 cells. These data indicate that
PDGF-BB may not be able to bind to the NRP1 extracellular
domain with high afﬁnity, although our results do not
preclude this possibility. NRP1 regulation of PDGF-BB-
induced migration may involve protein–protein associations
betweenNRP1andPDGFRs,sinceNRP1co-immunoprecipitated
with PDGFRα in HCASMCs. However, we were unable
to detect similar complex formation between PDGFRβ and
NRP1, indicating a preferential association with PDGFRα.
Since PDGFRα is a ligand for PDGF-BB and PDGF-AA
homodimers as well as PDGF-AB heterodimers, our results
suggest a possible mechanism in which PDGF-BB and PDGF-
AA act through PDGFRα–NRP1 complexes, resulting in optimal
chemotactic signalling. NRP1 siRNA-mediated knockdown also
caused a marked inhibition of PDGFRα activation in response
to PDGF-AA, and caused a signiﬁcant, but more modest,
reduction in PDGF-BB-induced PDGFRα activation, whereas
NRP1 knockdown did not affect PDGFRβ activity. Part of the
inhibition of PDGFRα could be due to a modest decrease in
surface PDGFRα expression resulting from NRP1 knockdown,
although we think this unlikely to wholly explain our results.
These results suggest that the constitutive association between
NRP1 and PDGFRα may contribute to receptor activity and at
least partly account for the role of NRP1 in PDGF responses
in VSMCs. The mechanism underlying the greater effect of
NRP1 knockdown on PDGF-AA-induced PDGFRα activity
compared with PDGF-BB is unclear, but PDGF-BB-induced
PDGFRα activation may reﬂect PDGF-BB binding to PDGFRαβ
heterodimersaswellasPDGFRααhomodimers,andheterodimer
activation may be independent of effects of NRP1 depletion.
Effects of PDGF-BB and PDGF-AA on PDGFRα activation can
be differentially regulated, for example by heparin [22]. It is of
note that selective NRP1 inhibition in endothelial cells, using
either antibodies or antagonistic peptides that speciﬁcally block
VEGF binding to NRP1 [13,23], only partially reduces VEGFR2
activity, indicating that NRP1 is not required for VEGFR2
activation in endothelial cells.
In the present study, we have shown that PDGF-BB stimulates
p130
Cas tyrosinephosphorylationandthatthisresponseispartially
inhibited by both NRP1 knockdown and by expression of the
NRP1 C mutant. PDGF-AA also stimulated p130
Cas tyrosine
phosphorylation and this effect was also reduced by NRP1
knockdown. In contrast, NRP1 siRNA had little signiﬁcant effect
on other PDGF-BB-stimulated signalling pathways, including
activation of ERK and Akt. p130
Cas is an adapter protein,
phosphorylated at multiple tyrosine residues, strongly implicated
in the migration of cancer cells and other cell types, and
known to associate with several proteins implicated in cell
migration [17]. In support of the conclusion that p130
Cas is a
key mediator of PDGF-BB-dependent chemotactic signalling,
p130
Cas knockdown inhibited migration in response to PDGF-
BB. We have also found that PDGF-BB induces p130
Cas
tyrosine phosphorylation via an NRP1-dependent mechanism in
U87MG glioblastoma cells, further supporting this conclusion
[24]. We are unaware of other reports showing PDGF-BB
regulationofp130
Cas tyrosinephosphorylationinVSMCsorother
cell types; indeed, PDGF-BB was shown to increase tyrosine
phosphorylation of the Cas family member HEF-1 (human
enhancer of ﬁlamentation 1), but not p130
Cas, in glioblastoma
cells [25]. These ﬁndings suggest that NRP1 is selectively
importantforoptimalPDGFRchemotacticsignallingviatyrosine
phosphorylation of p130
Cas. It remains unclear exactly how NRP1
is able to regulate p130
Cas phosphorylation, and investigation of
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Figure 8 Role of NRP1 O-linked glycosylation in PDGF-induced VSMC chemotaxis
(A and B) HCASMCs were incubated in serum-free medium overnight and then treated with chondroitinase, heparitinase or both enzymes combined (each at 1unit/ml) for 2h. Cells were then either
transferred to transwells and allowed to migrate for 4 h (A) in response to either 30ng/ml PDGF-BB or serum-free medium (Control), or were stimulated with PDGF-AA or PDGF-BB for 10min and
lysates were immunoblotted with the indicated antibodies (B). (C) HCASMCs were infected with Ad.GFP, Ad.NRP1WT or AD.NRP1S612A. At 3days after infection, cell lysates were prepared and
immunoblottedwithantibodiesagainstNRP1andGAPDH(upper),orweretransferredtotranswellsandallowedtomigratefor4hinresponsetoserum-freemedium(Control)or30ng/mlPDGF-AAor
PDGF-BB (lower). The values shown are mean+S.E.M. (n=3) numbers of migrated cells obtained from multiple independent experiments. *P <0.05 compared with Ad.NRP1WT plus PDGF-AA
or PDGF-BB. Molecular masses are indicated in kDa.
themolecularmechanismsinvolvedwarrantsfurtherexperimental
work.
Similar to previous studies [16,18], NRP1 is expressed in
VSMCs as a high-molecular-mass protein resulting from O-
linked glycosylation. Our results showed that enzymatic removal
of CS-GAGs in VSMCs reduced PDGF-induced migration
and p130
Cas tyrosine phosphorylation, and expression of an
NRP1S612A mutant non-modiﬁable by O-linked glycosylation
inhibited PDGF-induced cell migration. Since chondroitinase is
non-selectiveinremovingCS-GAGmoieties,itsoverallimpacton
cell migration and signalling is likely to be the complex outcome
of possibly both positive and negative effects, not attributable
only to NRP1 deglycosylation. The inhibition of migration by
NRP1S612A probably reﬂects a dominant-negative effect due to
the utilization of an overexpressed non-modiﬁed NRP1 by PDGF
rather than endogenous modiﬁed NRP1. Since NRP1S612A did
not inhibit p130
Cas phosphorylation, we conclude that the role of
NRP1 CS-GAG modiﬁcation in migration is distinct from the
role of NRP1 in PDGF signalling. It is possible that NRP1 CS-
GAG participates in interactions with matrix components of other
cell-associated molecules important for cell migration.
The ﬁndings of the present study indicate an important and
hitherto unrecognized role of NRP1 in PDGF cell signalling
in HCASMCs, and also identify a novel role of p130
Cas in
PDGF signalling mediating HCASMC migration. While this
work was under review, Ball et al. [26] reported that NRP1
associates with PDGFRα and mediates PDGF signalling in
mesenchymal stem cells, further consistent with our ﬁndings.
Our results suggest that NRP1-dependent mobilization of
p130
Cas tyrosine phosphorylation is a key mechanism in the
chemotactic response of VSMCs to PDGF, implicating this
pathway in the pathophysiological accumulation of VSMCs in
early atherosclerotic lesion formation, restenosis after balloon
angioplasty and other instances of neointimal thickening
contributing to vasculoproliferative pathologies. Further studies
should therefore examine the role of NRP1 in neointimal VSMC
accumulation in vivo.
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Figure S1 Immunoﬂuorescent localization of NRP1 and CS and HS in HCASMCs and HUVECs
HCASMCs (A and B) and HUVECs(C) were ﬁxed, permeabilized and then immunostained for NRP1 and co-stained with antibody for either CS (A and C)o rH S( B). NRP1 is located in the cytoplasm
and also at the membrane of the cells (A and B) where it co-localizes (indicated by white arrowheads) with CS (A) and HS (B). In HUVECs (C), such co-localization was not observed and rather
distinct signals are seen for CS and NRP1. Parallel cultures of HCASMCs (A and B) were also treated with chondroitinase (Case) and heparitinase (Hase) before ﬁxation and immunoﬂuorescent
staining. Results are representative of at least three independent experiments.
SUPPLEMENTARY METHODS
Receptor binding assay in intact cells
Conﬂuent HCASMCs, PAE cells and PAE/NRP1 cells cultured
in 24-well plates were washed twice with PBS. Binding medium
(Dulbecco’smodiﬁedEagle’smediumand25 mMHepes,pH 7.3,
containing 0.1% BSA) was added, followed by addition of
0.1 nM
125I-PDGF-BB (1825 Ci/mmol; Perkin-Elmer) or
125I-
VEGF-A165 (1200–1800 Ci/mmol; GE Healthcare). After 2 h of
incubation at 4 ◦C, the medium was aspirated and cells were
washed four times with ice-cold PBS. The cells were then lysed
with 0.25 M NaOH and 0.5% SDS solution, and radioactivity in
the lysates was measured in a γ-counter. Non-speciﬁc binding
was determined in the presence of a 100-fold excess of unlabelled
PDGF-BB or VEGF-A165 (R&D Systems).
PDGFR assay
In these assays of PDGFRs, an immobilized capture antibody
speciﬁc for human PDGFR binds both tyrosine-phosphorylated
and unphosphorylated PDGFR. After washing away unbound
material, a biotinylated detection antibody speciﬁc for total
PDGFR is used to detect both tyrosine-phosphorylated
and unphosphorylated receptor, utilizing streptavidin–HRP
(horseradish peroxidase), whereas an HRP-conjugated detection
antibody speciﬁc for phosphorylated tyrosine is used to detect
onlytyrosine-phosphorylatedreceptor,utilizingHRP.Thecapture
antibody was diluted to a working concentration of 4 μg/ml
in PBS, without carrier protein and 100 μl was immediately
added to a 96-well microplate for overnight incubation at room
temperature. The next day, each well was washed four times
with washing buffer (0.05% Tween 20 in PBS, pH 7.2) and
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Figure S2 VEGF does not induce migration or signalling in HCASMCs
(A and B) HCASMCs transferred to transwells were stimulated to migrate for 4h in response to serum-free medium (Control), 30ng/ml PDGF-BB or 30ng/ml VEGF-A165 (A), or in response to the
indicated VEGF concentrations (B). Cells were stained and counted as described in the Materials and methods section of the main text. Results are mean+S.E.M. (n = 3) numbers of migrated cells
obtained from multiple independent experiments. *P <0.05 compared with control. (C) Conﬂuent HCASMCs or HUVECs were treated for 10min with the indicated concentrations (all ng/ml) of
VEGF-A165, PDGF-AA or PDGF-BB. Lysates were prepared and blotted with the antibodies indicated. Results are representative of three independent experiments. Molecular masses are indicated
in kDa.
blocked for 2 h with 300 μl of PBS containing 1% BSA.
Wells were washed again three times before adding 100 μl
of lysate prepared in the following diluent: 1% Nonidet P40,
20 mM Tris/HCl (pH 8.0), 137 mM NaCl, 10% glycerol, 2 mM
EDTA and 1 mM activated sodium orthovanadate. The same
diluent without protein was used as a blank. The plate was
left to incubate for 2 h at room temperature and washed again.
Then, 100 μl of detection antibody diluted to the manufacturer’s
recommendations in 20 mM Tris/HCl, 137 mM NaCl, 0.05%
Tween 20 and 0.1% BSA (pH 7.2) was added directly to the
well, before incubation for a further 2 h. When measuring total
PDGFR levels, the following extra step was required: after
another three washes, streptavidin–HRP was diluted according
to the manufacturer’s recommendations in the same buffer as
the detection antibody and 100 μl was added to each well
for 20 min at room temperature. Finally, 100 μl of substrate
solution was added to each well for 20 min, followed by
50 μl of stop solution. The absorbance of each well was
determined immediately, using a microplate reader set to 450 nm
with wavelength correction of 595 nm. The values obtained for
phospho-PDGFRs were normalized using the values obtained for
total PDGFRs.
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Figure S3 PDGFRβ and NRP1 do not co-localize in HCASMCs
HCASMCswereﬁxed,permeabilizedandthenimmunostainedforNRP1(green)andco-stained
with antibodyfor PDGFRβ (red).NRP1 is located in the cytoplasm and also at the membraneof
the cells, and in the merge shows little co-localization with PDGFRβ in the membrane (bottom
panels). Some co-localization can be observed in the cytoplasm (white arrowheads).
Table S1 Binding of 125I-PDGF-BB or 125I-VEGF-A165 was determined in
intact conﬂuent cultures of HCASMCs, PAE cells or PAE/NRP1 cells in the
presence or absence of a 100-fold excess of unlabelled PDGF-BB or VEGF
Non-speciﬁc binding was deﬁned as that which is not competed by an excess of unlabelled
ligand. Speciﬁc binding was calculated by subtracting non-speciﬁc binding from total counts.
Results are mean counts (c.p.m.) obtained from three independent experiments, with each
experiment being performed in triplicate wells. Percentages of total binding are indicated in
parentheses.
125I-ligand binding (c.p.m.)
Growth factor Cell type Total Non-speciﬁc Speciﬁc
PDGF-BB HCASMCs 6542 (100) 2600 (40) 3942 (60)
PAE cells 13899 (100) 11857 (85) 2042 (15)
PAE/NRP1 cells 13363 (100) 10626 (80) 2737 (20)
VEGF HCASMCs 1595 (100) 726 (46) 868 (54)
PAE/NRP1 cells 4137 (100) 688 (17) 3448 (83)
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Figure S4 PDGF-stimulated p130Cas phosphorylation is mediated via NRP1
HCASMCs were transfected with control scrambled siRNA (scr) or with NRP1 siRNA, and
3 days later, cells were incubated overnight in serum-free medium and then treated for the
times indicated (in min) with 30ng/ml PDGF-BB. Cells were then lysed and immunoblotted
with the antibodies indicated. The results shown are representative of at least three independent
experiments. Molecular masses are indicated in kDa.
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